348 related articles for article (PubMed ID: 20027224)
1. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.
Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW
PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224
[TBL] [Abstract][Full Text] [Related]
2. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
[TBL] [Abstract][Full Text] [Related]
3. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
4. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.
Fang M; Ou J; Hutchinson L; Green MR
Mol Cell; 2014 Sep; 55(6):904-915. PubMed ID: 25219500
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation instability by BRAF-mediated TET silencing and lifestyle-exposure divides colon cancer pathways.
Noreen F; Küng T; Tornillo L; Parker H; Silva M; Weis S; Marra G; Rad R; Truninger K; Schär P
Clin Epigenetics; 2019 Dec; 11(1):196. PubMed ID: 31842975
[TBL] [Abstract][Full Text] [Related]
6. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype.
Suzuki H; Igarashi S; Nojima M; Maruyama R; Yamamoto E; Kai M; Akashi H; Watanabe Y; Yamamoto H; Sasaki Y; Itoh F; Imai K; Sugai T; Shen L; Issa JP; Shinomura Y; Tokino T; Toyota M
Carcinogenesis; 2010 Mar; 31(3):342-9. PubMed ID: 19638426
[TBL] [Abstract][Full Text] [Related]
7. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
8. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer.
Wong JJ; Hawkins NJ; Ward RL; Hitchins MP
Mod Pathol; 2011 Mar; 24(3):396-411. PubMed ID: 21102416
[TBL] [Abstract][Full Text] [Related]
9. High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients.
Naghibalhossaini F; Hosseini HM; Mokarram P; Zamani M
Pathol Oncol Res; 2011 Dec; 17(4):819-25. PubMed ID: 21455633
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis.
Ogino S; Brahmandam M; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
Mod Pathol; 2006 Aug; 19(8):1083-90. PubMed ID: 16699497
[TBL] [Abstract][Full Text] [Related]
11. Genome-scale analysis of aberrant DNA methylation in colorectal cancer.
Hinoue T; Weisenberger DJ; Lange CP; Shen H; Byun HM; Van Den Berg D; Malik S; Pan F; Noushmehr H; van Dijk CM; Tollenaar RA; Laird PW
Genome Res; 2012 Feb; 22(2):271-82. PubMed ID: 21659424
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
[TBL] [Abstract][Full Text] [Related]
13. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
[TBL] [Abstract][Full Text] [Related]
14. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
[TBL] [Abstract][Full Text] [Related]
15. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
[TBL] [Abstract][Full Text] [Related]
16. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
[TBL] [Abstract][Full Text] [Related]
17. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.
Weisenberger DJ; Siegmund KD; Campan M; Young J; Long TI; Faasse MA; Kang GH; Widschwendter M; Weener D; Buchanan D; Koh H; Simms L; Barker M; Leggett B; Levine J; Kim M; French AJ; Thibodeau SN; Jass J; Haile R; Laird PW
Nat Genet; 2006 Jul; 38(7):787-93. PubMed ID: 16804544
[TBL] [Abstract][Full Text] [Related]
18. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
19. Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups.
Bond CE; Bettington ML; Pearson SA; McKeone DM; Leggett BA; Whitehall VL
BMC Cancer; 2015 Jan; 15():20. PubMed ID: 25613750
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
